ProCE Banner Activity

Monitoring Ocular AEs in Women With Gynecologic Cancers Receiving Antibody-Drug Conjugates

Clinical Thought

In this commentary, a board-certified ophthalmologist describes his role in caring for patients with gynecologic cancers who are receiving antibody-drug conjugates.

Released: June 16, 2022

Expiration: June 15, 2023

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Acknowledgement

This activity is supported by an educational grant from Genmab and Seagen.

Supporters

Genmab

Seagen

Target Audience

Oncology NPs, PAs, and nurses

Disclosure

Asim V. Farooq, MD: consultant/advisor/speaker: Ambrx, Amgen, Eisai, GlaxoSmithKline, Sanofi, Seagen.

Format

ClinicalThought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.